rhNGF 10 μg/ml

DRUG2 trials

Sponsors

Dompé Farmaceutici S.p.A

Conditions

Corneal UlcerDry Eye DiseaseKeratitisNeurotrophic Keratitis

Phase 1

Evaluation of Safety and Efficacy of rhNGF in Patients With Stage 2 and 3 Neurotrophic Keratitis.

CompletedNCT01756456

Dompé Farmaceutici S.p.ACorneal Ulcer, Keratitis, Neurotrophic Keratitis

Start: 2013-01-31End: 2016-05-31Updated: 2024-04-19

Phase 2

A Safety and Efficacy Study of 2 Dosing Regimens of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution Compared With Vehicle in Patients With Dry Eye Disease.

CompletedNCT06244316

Dompé Farmaceutici S.p.ADry Eye Disease

Start: 2024-01-22End: 2024-12-04Updated: 2026-02-13

Related Papers

Neurotrophic factors: promising candidates in tissue regeneration

Neural Regeneration Research2016-01-0113 citations

Potential New Modes of Treatment of Neurotrophic Keratopathy.

2015-11-0124 citations

Safety and pharmacokinetics of escalating doses of human recombinant nerve growth factor eye drops in a double-masked, randomized clinical trial.

2014-06-0164 citations